Pradaxa Pediatric (dabigatran etexilate pellets) (Dabigatran Etexilate CAPSULE) 110 mg/1

Pradaxa Pediatric (dabigatran etexilate) is an oral direct thrombin inhibitor approved by the FDA as an orphan drug for the treatment of venous thromboembolism (VTE) in pediatric patients. This innovative anticoagulant represents a significant therapeutic advance in pediatric hematology, offering an alternative to traditional anticoagulation therapies in this vulnerable population.

Strength

110 mg/1

Pack Size

1 BOTTLE in 1 CARTON (0597-0108-54) / 60 CAPSULE in 1 BOTTLE

Manufacturer / TM Owner

Boehringer Ingelheim

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Pradaxa Pediatric is indicated for the treatment and prevention of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in pediatric patients. The drug is specifically designed for children who require anticoagulation therapy but may have limitations with conventional treatments such as warfarin or low-molecular-weight heparin. Dabigatran etexilate works as a direct thrombin inhibitor, selectively and reversibly binding to thrombin to prevent thrombus formation and progression. The pediatric formulation addresses the critical unmet medical need in children with VTE, a rare but serious condition that can result from various etiologies including malignancy, central venous catheters, surgery, or inherited thrombophilia. By providing an oral anticoagulant option with predictable pharmacokinetics, Pradaxa Pediatric improves treatment adherence and quality of life compared to injectable alternatives.

Side Effects

Common adverse effects of Pradaxa Pediatric include bleeding manifestations ranging from minor bruising and epistaxis to gastrointestinal bleeding. Serious adverse events include major hemorrhage, intracranial bleeding, and thrombotic complications. Patients may experience dyspepsia, abdominal discomfort, and gastrointestinal disturbances. Monitoring requirements include baseline and periodic coagulation assessments, renal function tests, and hepatic function evaluation. Patients and caregivers should be educated on signs of bleeding and instructed to report unusual bruising, blood in urine or stool, hemoptysis, or neurological symptoms immediately. Regular follow-up appointments are essential to assess treatment efficacy and tolerability.

Precautions & Warnings

Pradaxa Pediatric is contraindicated in patients with active pathological bleeding or hypersensitivity to dabigatran etexilate. Caution is warranted in pediatric patients with renal impairment, as dabigatran is renally eliminated. Hepatic dysfunction may affect drug metabolism and requires dose adjustment consideration. The drug should be used cautiously in children with mechanical heart valves or severe thrombophilia. Pregnancy and lactation data are limited; use should be carefully evaluated in adolescent females of childbearing potential. Patients undergoing invasive procedures may require temporary discontinuation. Close monitoring is essential in children with bleeding disorders, thrombocytopenia, or concurrent use of other anticoagulants or antiplatelet agents.

Avoid Interactions

Dabigatran etexilate is a substrate of P-glycoprotein; concurrent use of potent P-glycoprotein inhibitors (such as ketoconazole, itraconazole, or ritonavir) may increase dabigatran exposure and bleeding risk. P-glycoprotein inducers may reduce dabigatran levels. Concurrent antiplatelet agents, NSAIDs, and other anticoagulants increase bleeding risk and should be used cautiously. Aspirin and other antiplatelet drugs require careful consideration. Certain antibiotics and antifungals may interact. Food does not significantly affect dabigatran absorption, but consistent administration timing is recommended.

Frequently Asked Questions

Pradaxa Pediatric is used to treat and prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in pediatric patients. It is an oral anticoagulant that works by inhibiting thrombin, the enzyme responsible for blood clot formation. This orphan drug addresses the critical need for effective anticoagulation therapy in children.

Pradaxa Pediatric is administered orally, with dosing based on the child's weight and age as determined by the prescribing physician. The pediatric formulation is available in a liquid suspension to facilitate accurate dosing in children. Doses should be taken consistently at the same times each day for optimal efficacy.

Common side effects include bleeding manifestations such as bruising and nosebleeds, gastrointestinal symptoms including dyspepsia and abdominal discomfort, and minor bleeding events. Serious side effects may include major hemorrhage and intracranial bleeding. Any signs of unusual bleeding should be reported to a healthcare provider immediately.

Pradaxa Pediatric is manufactured by Boehringer Ingelheim, a leading pharmaceutical company specializing in innovative medications for serious diseases.

Yes, Pradaxa Pediatric has been designated and approved as an orphan drug by the FDA. This designation recognizes its importance in treating a rare condition (VTE in pediatric patients) and reflects the significant unmet medical need in this vulnerable population. Orphan drug status provides regulatory incentives and support for development and commercialization.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.